RadNet Earnings Call Highlights AI-Driven Growth

Radnet ((RDNT)) has held its Q1 earnings call. Read on for the main highlights of the call.

RadNet’s latest earnings call struck a confident tone, highlighting record first quarter results, accelerating growth in advanced imaging and digital health, and visible productivity gains from artificial intelligence deployments. Management acknowledged weather headwinds, short‑term margin pressure in Digital Health and normal seasonal costs, but stressed that raised guidance and strong liquidity support a durable growth story.

Record Q1 Revenue and Adjusted EBITDA

RadNet reported a standout first quarter, with revenue climbing 22.1% year over year and adjusted EBITDA jumping 36.3%, setting new Q1 records for the company. Adjusted EBITDA margin expanded by 115 basis points versus the prior‑year period, and even after normalizing for weather and wildfire impacts, margin still improved by 52 basis points, underscoring solid operating leverage.

Strong Advanced-Imaging Mix and Same-Center Volume Growth

Advanced imaging continued to be the main growth engine, representing 29.3% of total procedures compared with 26.9% a year earlier, a 235‑basis‑point gain in mix. Same‑center advanced imaging volumes rose 8.2%, led by roughly 10.1% growth in MRI, mid‑single‑digit gains in CT and a 35.2% surge in PET/CT overall, helping advanced imaging generate more than 60% of company revenue despite being less than one‑third of volume.

Digital Health Momentum and ARR Growth

The DeepHealth digital platform posted sharp acceleration, exiting the quarter with $97 million in annual recurring revenue, up 95% from a year ago, and management reiterated a goal of surpassing $140 million by year‑end. New commercial wins totaled $16 million in contract value across about 40 customers, with $7 million of signed ARR not yet live and a pipeline above $150 million in total contract value, while external revenue mix in Digital Health rose to 64% from 51%.

Guidance Raised for Imaging Center Business

On the back of stronger‑than‑expected trends in March that carried into April and May, RadNet increased its 2026 outlook for the Imaging Center segment, lifting both the low and high ends of revenue guidance by $30 million. The company also raised adjusted EBITDA guidance by $5 million at each end and boosted free cash flow expectations by $7 million, signaling confidence that current momentum in core imaging can be sustained.

Strategic Acquisitions and JV Expansion

RadNet continued to expand its footprint through acquisitions and partnerships, closing deals for Radiology Regional in Southwest Florida, Northwest Radiology in Indiana and AI company Gleamer in France. It also launched a new 51% joint venture with Trinity Health St. Alphonsus in Boise, Idaho, in an entity generating roughly $30 million in annual revenue, bringing 155 of its 440 centers into health system partnerships and creating additional channels for deploying DeepHealth solutions.

Operational Productivity and AI Deployments

Management emphasized tangible productivity gains from technology, noting that TechLive remote scanning reduced exam room downtime and improved MRI utilization across the network. AI tools are being rolled out at scale, with thyroid ultrasound algorithms cutting scan slots from 30 minutes to 20 minutes at nearly 300 sites, X‑ray AI now live in California covering over 20% of regional volume and DeepHealth plus third‑party AI touching about 70% of studies across mammography, MR, CT, ultrasound and X‑ray.

Strong Liquidity and Improved Receivables

The balance sheet remains a key support, with quarter‑end cash of $455.3 million and full availability under a $282 million revolving credit facility, giving RadNet ample room to fund growth and integration. Net debt stood at $631 million, translating to a net debt to adjusted EBITDA ratio of roughly 2.0 times, while days sales outstanding fell to a record low 29.5 days thanks to stronger patient collections and revenue‑cycle improvements.

Regulatory and Product Acceleration

DeepHealth’s regulatory pipeline is gathering speed, with 26 FDA clearances and 22 CE marks already obtained for its AI portfolio and expectations for roughly 12 more FDA and 15 additional CE approvals this year. Management highlighted that the pace of regulatory approvals has increased more than 70% year over year, supporting faster commercialization and broadened clinical use of its AI offerings.

Severe Weather Impact on Q1 Results

Despite the strong headline numbers, the company estimated that severe winter storms on the East Coast in January and February reduced first quarter revenue by about $13 million and adjusted EBITDA by roughly $9 million. Management also reminded investors that the prior‑year quarter was affected by similar weather issues and Southern California wildfires, underscoring that the business has delivered growth despite recurring climate‑related disruptions.

Digital Health Short-Term Margin Dilution

Digital Health profitability was intentionally compressed in the quarter as RadNet absorbed the impact of recent acquisitions and ramped up infrastructure and deployment investments, with management describing Q1 as the trough for segment margins. Some deals, such as Gleamer, are initially dilutive and will take time to scale to target profitability, while stepped‑up spending on commercial capabilities is temporarily weighing on adjusted EBITDA in exchange for higher long‑term growth.

Seasonality and First-Quarter Expense Pressures

Management reminded investors that the first quarter is seasonally the weakest for EBITDA, due to deductible resets, winter‑driven demand patterns and payroll taxes that cap out early for highly compensated clinicians. In addition, the company typically expenses bonuses in Q1, which depresses reported profitability in the period but tends to normalize over the balance of the year as volumes and mix improve.

Reimbursement and Payer Uncertainty for AI

While AI is delivering efficiency gains, the reimbursement landscape remains uneven, with insurers adopting new codes at different speeds and coverage tiers, creating near‑term uncertainty around direct monetization. As one example, coverage for a thyroid ultrasound T‑code has risen from roughly a quarter of payers to about 60–70%, but broader reimbursement for other AI‑enabled modalities will require continued deployment, billing adoption and sustained engagement with payers as regulators finalize future payment schedules.

Increased Leverage from Acquisitions

The recent slate of acquisitions has increased leverage, as RadNet deployed significant cash to secure Radiology Regional, Northwest Radiology and Gleamer, even as it maintained a robust cash position. Management framed the higher net debt as a temporary step‑up and reiterated expectations to deleverage over coming quarters through free cash flow, suggesting that the company views current balance sheet risk as manageable in light of growth opportunities.

Routine Imaging Growth Slower than Advanced Imaging

Routine imaging volumes were essentially flat in the quarter, and management signaled it expects only low single‑digit growth in these basic modalities despite the fact they still comprise about 71% of total procedures. This dynamic places a premium on expanding capacity and share in advanced imaging, where demand and pricing are stronger, and where the company sees the clearest path to sustained revenue and margin expansion.

Forward-Looking Guidance and Outlook

Looking ahead, RadNet’s raised 2026 imaging guidance and reaffirmed Digital Health targets point to continued confidence in both core imaging and its AI‑driven platform, underpinned by record Q1 revenue, faster advanced‑imaging growth and nearly doubled ARR. With cash of $455.3 million, net leverage around 2.0 times and record low DSO, management believes it has the financial flexibility to integrate acquisitions, invest in Digital Health and navigate reimbursement uncertainty while pursuing higher‑margin growth.

RadNet’s earnings call painted a picture of a company leaning into secular trends in advanced imaging and AI while managing the trade‑offs of near‑term margin pressure and acquisition‑driven leverage. For investors, the key takeaways are robust top‑line growth, rising recurring digital revenue, stronger guidance and visible productivity gains from technology, all set against manageable risks from seasonality, weather and evolving AI reimbursement.